September 11, 2024 03:01 PM EDT
R&D

No­vo Nordisk's long­stand­ing GLP-1 re­duced BMI by 7% in chil­dren in Phase 3 tri­al

Katherine Lewin

News Reporter

No­vo Nordisk said chil­dren be­tween the ages of 6 and 12 saw a 7.4% re­duc­tion in BMI over about a year in a late-stage tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times